Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GM-CSF, fosfomycin and metronidazole for pouchitis after IPAA
2024-517764-38-00Phase 2Authorised
- Sponsor
- Reponex Pharmaceuticals
- Start
- Sep 2024
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sargramostim, fosfomycin and metronidazole in pouchitis, sponsored by Reponex Pharmaceuticals. Primary endpoint: Change in the pouchitis disease activity index (PDAI). Planned start Sep 2024; status: authorised.
02
Drugs
sargramostimfosfomycinmetronidazole
03
Conditions
pouchitis
Beyond the preview
Go deeper on 2024-517764-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517764-38-00.